In this sense, the methylation status of SOCS3 has been proposed as a malignant prognostic biomarker [17], and the differential expression of SOCS1 and SOCS3 in GBM has been studied as putative factors involved in radiotherapy resistance [18]. This evidence concerns the gene SOCS3 and glioblastoma.